[1].甲状腺结节和分化型甲状腺癌诊治指南(第二版)[J].国际内分泌代谢杂志,2023,43(02):149-194.[doi:10.3760/cma.j.cn311282-20221023-00589]
　Chinese Society of Endocrinology,Thyroid and Metabolism Surgery Group of the Chinese Society of Surgery,China Anti-Cancer Association,et al.Guidelines for the Diagnosis and Management of Thyroid Nodules and Differentiated Thyroid Cancer(Second Edition)[J].International Journal of Endocrinology and Metabolism,2023,43(02):149-194.[doi:10.3760/cma.j.cn311282-20221023-00589]
点击复制

甲状腺结节和分化型甲状腺癌诊治指南(第二版)()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
43
期数:
2023年02期
页码:
149-194
栏目:
指南与共识
出版日期:
2023-03-20

文章信息/Info

Title:
Guidelines for the Diagnosis and Management of Thyroid Nodules and Differentiated Thyroid Cancer(Second Edition)
Author(s):
Chinese Society of Endocrinology; Thyroid and Metabolism Surgery Group of the Chinese Society of Surgery; China Anti-Cancer Association;  Chinese Association of Head and Neck Oncology; Chinese Society of Nuclear Medicine; China Anti-Cancer Association;  Chi
关键词:
甲状腺结节;  分化型甲状腺癌;  诊治指南
Keywords:
Thyroid nodules;  Differentiated thyroid cancer;  Guidelines
DOI:
10.3760/cma.j.cn311282-20221023-00589
摘要:
中国《甲状腺结节和分化型甲状腺癌诊治指南》(第二版)是在第一版(2012年版)的基础上进行的修订。参与第二版指南修订的国家级学会由4个增加为7个,内分泌科、甲状腺外科、肿瘤科、核医学科、超声医学科和病理科专家都参与了本指南的编撰,增加了指南的权威性。指南采用最佳的临床证据并综合专家意见给出了117条推荐,内容全面而系统。明确了甲状腺结节的筛查人群,增加了超声鉴别甲状腺结节良恶性的中国标准,提出了超声引导下的细针抽吸活检和粗针活检的适应证,对分化型甲状腺癌术前评估、术式、术后分期、随访、131I治疗、促甲状腺激素抑制治疗、靶向药物治疗以及新兴的治疗方法给予了比较全面和客观的修订。第二版指南将为进一步指导和规范甲状腺结节和甲状腺癌的诊断治疗发挥积极的推动作用。
Abstract:
The Chinese guidelines for the diagnosis and management of thyroid nodules and differentiated thyroid cancer(Second edition)were revised on the basis of the 2012 edition. The number of national societies involved in the revision increased from four to seven, endocrinology, thyroid surgery, oncology, nuclear medicine, ultrasound, and pathology, which enhanced the authority of the guidelines. The guideline is comprehensive and systematic with 117 recommendations based on the best clinical evidence and expert opinion. The guideline clarifies the population clusters for thyroid nodules screening, draws up the Chinese standard of ultrasound for differentiating benign and malignant thyroid nodules and proposes the indications of ultrasound-guided fine-needle aspirations biopsy and core needle biopsy. It effectuates a more comprehensive and objective revision for preoperative evaluation, surgical procedures, postoperative staging, follow-up strategy, 131I therapy, thyroid stimulating hormone suppressive therapy, targeted medication, and emerging therapeutic methods for differentiated thyroid cancer. The edition will be an active impetus in improving the diagnosis and therapeutic landscape of thyroid nodules and differentiated thyroid cancer in China.

参考文献/References:

[1] Li Y, Teng D, Ba J, et al. Efficacy and Safety of Long-Term Universal Salt Iodization on Thyroid Disorders: Epidemiological Evidence from 31 Provinces of Mainland China[J]. Thyroid, 2020,30(4):568-579. DOI: 10.1089/thy.2019.0067.
[2] 中华医学会内分泌学分会, 中华医学会外科学分会内分泌学组, 中国抗癌协会头颈肿瘤专业委员会, 等. 甲状腺结节和分化型甲状腺癌诊治指南[J]. 中华内分泌代谢杂志, 2012,28(10):779-797. DOI: 10.3760/cma.j.issn.1000-6699.2012.10.002.
[3] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016,26(1):1-133. DOI: 10.1089/thy.2015.0020.
[4] Marqusee E, Benson CB, Frates MC, et al. Usefulness of ultrasono-graphy in the management of nodular thyroid disease[J]. Ann Intern Med, 2000,133(9):696-700. DOI: 10.7326/0003-4819-133-9-200011070-00011.
[5] Durante C, Grani G, Lamartina L, et al. The Diagnosis and manag-ement of thyroid nodules: a review[J]. JAMA, 2018,319(9):914-924. DOI: 10.1001/jama.2018.0898.
[6] Durante C, Costante G, Lucisano G, et al. The natural history of benign thyroid nodules[J]. JAMA, 2015,313(9):926-935. DOI: 10.1001/jama.2015.0956.
[7] Ye L, Zhou X, Huang F, et al. The genetic landscape of benign thyroid nodules revealed by whole exome and transcriptome sequencing[J]. Nat Commun, 2017,8:15533. DOI: 10.1038/ncomms15533.
[8] Lin JS, Bowles E, Williams SB, et al. Screening for Thyroid Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force[J]. JAMA, 2017,317(18):1888-1903. DOI: 10.1001/jama.2017.0562.
[9] Lee YS, Lim H, Chang HS, et al. Papillary thyroid microcarcinomas are different from latent papillary thyroid carcinomas at autopsy[J]. J Korean Med Sci, 2014,29(5):676-679. DOI: 10.3346/jkms.2014.29.5.676.
[10] La Vecchia C, Negri E. Thyroid cancer: The thyroid cancer epidemic-overdiagnosis or a real increase?[J]. Nat Rev Endocrinol, 2017,13(6):318-319. DOI: 10.1038/nrendo.2017.53.
[11] 陈孝平, 汪建平, 赵继宗. 外科学[M]. 9版. 北京:人民卫生出版社, 2018.
[12] Suh I, Vriens MR, Guerrero MA, et al. Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cell neoplasms of the thyroid[J]. Am J Surg, 2010,200(1):41-46. DOI: 10.1016/j.amjsurg.2009.08.030.
[13] Chambon G, Alovisetti C, Idoux-Louche C, et al. The use of preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid disorders: results from 2733 consecutive patients[J]. J Clin Endocrinol Metab, 2011,96(1):75-81. DOI: 10.1210/jc.2010-0162.
[14] Gharib H, Papini E, Garber JR, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules—2016 Update [J]. Endocr Pract, 2016,22(5):622-639. DOI: 10.4158/EP161208.GL.
[15] Grant EG, Tessler FN, Hoang JK, et al. Thyroid Ultrasound Reporting Lexicon: White Paper of the ACR Thyroid Imaging, Reporting and Data System(TIRADS)Committee[J]. J Am Coll Radiol, 2015,12(12 Pt A):1272-1279. DOI: 10.1016/j.jacr.2015.07.011.
[16] Lee JY, Baek JH, Ha EJ, et al. 2020 Imaging Guidelines for Thyroid Nodules and Differentiated Thyroid Cancer: Korean Society of Thyroid Radiology[J]. Korean J Radiol, 2021,22(5):840-860. DOI: 10.3348/kjr.2020.0578.
[17] 中华医学会超声医学分会浅表器官和血管学组, 中国甲状腺与乳腺超声人工智能联盟. 2020甲状腺结节超声恶性危险分层中国指南: C-TIRADS[J]. 中华超声影像学杂志, 2021,30(3):185-200. DOI: 10.3760/cma.j.cn131148-20210205-00092.
[18] Leenhardt L, Erdogan MF, Hegedus L, et al. 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer[J]. Eur Thyroid J, 2013,2(3):147-159. DOI: 10.1159/000354537.
[19] Kwak JY, Han KH, Yoon JH, et al. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratific-ation of cancer risk[J]. Radiology, 2011,260(3):892-899. DOI: 10.1148/radiol.11110206.
[20] Amin MB, Edge SB, Greene FL. AJCC Cancer Staging Manual(8th Edition)[M]. NewYork: Springer, 2017.
[21] Prativadi R, Dahiya N, Kamaya A, et al. Chapter 5 Ultrasound Characteristics of Benign vs Malignant Cervical Lymph Nodes[J]. Semin Ultrasound CT MR, 2017,38(5):506-515. DOI: 10.1053/j.sult.2017.05.005.
[22] Ryu KH, Lee KH, Ryu J, et al. Cervical Lymph Node Imaging Reporting and Data System for Ultrasound of Cervical Lymphadenopathy: A Pilot Study[J]. AJR Am J Roentgenol, 2016,206(6):1286-1291. DOI: 10.2214/AJR.15.15381.
[23] Xing Z, Qiu Y, Yang Q, et al. Thyroid cancer neck lymph nodes metastasis: Meta-analysis of US and CT diagnosis[J]. Eur J Radiol, 2020,129:109103. DOI: 10.1016/j.ejrad.2020.109103.
[24] Zhao CK, Xu HX. Ultrasound elastography of the thyroid: principles and current status[J]. Ultrasonography, 2019,38(2):106-124. DOI: 10.14366/usg.18037.
[25] Cosgrove D, Barr R, Bojunga J, et al. WFUMB Guidelines and Recommendations on the Clinical Use of Ultrasound Elastography: Part 4. Thyroid[J]. Ultrasound Med Biol, 2017,43(1):4-26. DOI: 10.1016/j.ultrasmedbio.2016.06.022.
[26] Zhang B, Jiang YX, Liu JB, et al. Utility of contrast-enhanced ultrasound for evaluation of thyroid nodules[J]. Thyroid, 2010,20(1):51-57. DOI: 10.1089/thy.2009.0045.
[27] Yue WW, Qi L, Wang DD, et al. US-guided Microwave Ablation of Low-Risk Papillary Thyroid Microcarcinoma: Longer-Term Results of a Prospective Study[J]. J Clin Endocrinol Metab, 2020,105(6):1791-1800. DOI: 10.1210/clinem/dgaa128.
[28] Li X, Zhang S, Zhang Q, et al. Diagnosis of thyroid cancer using deep convolutional neural network models applied to sonographic images: a retrospective, multicohort, diagnostic study[J]. Lancet Oncol, 2019,20(2):193-201. DOI: 10.1016/S1470-2045(18)30762-9.
[29] Zhao CK, Ren TT, Yin YF, et al. A Comparative Analysis of Two Machine Learning-Based Diagnostic Patterns with Thyroid Imaging Reporting and Data System for Thyroid Nodules: Diagnostic Performance and Unnecessary Biopsy Rate[J]. Thyroid, 2021,31(3):470-481. DOI: 10.1089/thy.2020.0305.
[30] Chan WK, Sun JH, Liou MJ, et al. Using Deep Convolutional Neural Networks for Enhanced Ultrasonographic Image Diagnosis of Differentiated Thyroid Cancer[J]. Biomedicines, 2021,9(12):1771. DOI: 10.3390/biomedicines9121771.
[31] 郭又铭, 霍金龙, 瞿锐, 等. 无负压对比负压细针穿刺在甲状腺结节中比较的Meta分析[J]. 临床耳鼻咽喉头颈外科杂志, 2018,32(11):868-872. DOI: 10.13201/j.issn.1001-1781.2018.11.017.
[32] Suh CH, Baek JH, Lee JH, et al. The role of core-needle biopsy in the diagnosis of thyroid malignancy in 4580 patients with 4746 thyroid nodules: a systematic review and meta-analysis[J]. Endocrine, 2016,54(2):315-328. DOI: 10.1007/s12020-016-0991-9.
[33] Chae IH, Kim EK, Moon HJ, et al. Ultrasound-guided fine needle aspiration versus core needle biopsy: comparison of post-biopsy hema-toma rates and risk factors[J]. Endocrine, 2017,57(1):108-114. DOI: 10.1007/s12020-017-1319-0.
[34] Ito Y, Amino N, Yokozawa T, et al. Ultrasonographic evaluation of thyroid nodules in 900 patients: comparison among ultrasonographic, cytological, and histological findings[J]. Thyroid, 2007,17(12):1269-1276. DOI: 10.1089/thy.2007.0014.
[35] Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology[J]. Thyroid, 2017,27(11):1341-1346. DOI: 10.1089/thy.2017.0500.
[36] Grani G, Fumarola A. Thyroglobulin in lymph node fine-needle aspiration washout: a systematic review and meta-analysis of diagnostic accuracy[J]. J Clin Endocrinol Metab, 2014,99(6):1970-1982. DOI: 10.1210/jc.2014-1098.
[37] Liu Z, Zhou W, Han R, et al. Cytology versus calcitonin assay in fine-needle aspiration biopsy wash-out fluid(FNAB-CT)in diagnosis of medullary thyroid microcarcinoma[J]. Endocrine, 2021,74(2):340-348. DOI: 10.1007/s12020-021-02759-1.
[38] Fnais N, Soobiah C, Al-Qahtani K, et al. Diagnostic value of fine needle aspiration BRAF(V600E)mutation analysis in papillary thyroid cancer: a systematic review and meta-analysis[J]. Hum Pathol, 2015,46(10):1443-1454. DOI: 10.1016/j.humpath.2015.06.001.
[39] Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules[J]. J Clin Endocrinol Metab, 2009,94(6):2092-2098. DOI: 10.1210/jc.2009-0247.
[40] Fazeli SR, Zehr B, Amraei R, et al. ThyroSeq v2 Testing: Impact on Cytologic Diagnosis, Management, and Cost of Care in Patients with Thyroid Nodule[J]. Thyroid, 2020,30(10):1528-1534. DOI: 10.1089/thy.2019.0191.
[41] Livhits MJ, Zhu CY, Kuo EJ, et al. Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial[J]. JAMA Oncol, 2021,7(1):70-77. DOI: 10.1001/jamaoncol.2020.5935.
[42] Giovanella L, Avram AM, Iakovou I, et al. EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy[J]. Eur J Nucl Med Mol Imaging, 2019,46(12):2514-2525. DOI: 10.1007/s00259-019-04472-8.
[43] Soelberg KK, Bonnema SJ, Brix TH, et al. Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review[J]. Thyroid, 2012,22(9):918-925. DOI: 10.1089/thy.2012.0005.
[44] Kwak JY, Koo H, Youk JH, et al. Value of US correlation of a thyroid nodule with initially benign cytologic results[J]. Radiology, 2010,254(1):292-300. DOI: 10.1148/radiol.2541090460.
[45] Oertel YC, Miyahara-Felipe L, Mendoza MG, et al. Value of repeated fine needle aspirations of the thyroid: an analysis of over ten thousand FNAs[J]. Thyroid, 2007,17(11):1061-1066. DOI: 10.1089/thy.2007.0159.
[46] Wharry LI, McCoy KL, Stang MT, et al. Thyroid nodules(≥4 cm): can ultrasound and cytology reliably exclude cancer?[J]. World J Surg, 2014,38(3):614-621. DOI: 10.1007/s00268-013-2261-9.
[47] Bakkar S, Poma AM, Corsini C, et al. Underestimated risk of cancer in solitary thyroid nodules ≥3 cm reported as benign[J]. Langenbecks Arch Surg, 2017,402(7):1089-1094. DOI: 10.1007/s00423-017-1600-y.
[48] Patel KN, Yip L, Lubitz CC, et al. The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults[J]. Ann Surg, 2020,271(3):e21-e93. DOI: 10.1097/SLA.0000000000003580.
[49] 中国医师协会外科医师分会甲状腺外科医师委员会, 中国研究型医院学会甲状腺疾病专业委员会, 中国医疗保健国际交流促进会临床实用技术分会. 甲状腺功能亢进症外科治疗中国专家共识(2020版)[J]. 中国实用外科杂志, 2020,40(11):1229-1233. DOI: 10.19538/j.cjps.issn1005-2208.2020.11.01.
[50] 田文, 费阳, 郗洪庆. 甲状腺手术中新技术的合理应用及展望[J]. 中国实用外科杂志, 2018,38(6):600-604. DOI: 10.19538/j.cjps.issn1005-2208.2018.06.03.
[51] 中华医学会内分泌学分会. 成人甲状腺功能减退症诊治指南[J]. 中华内分泌代谢杂志, 2017,33(2):167-180. DOI: 10.3760/cma.j.issn.1000-6699.2017.02.018.
[52] Hermus AR, Huysmans DA. Treatment of benign nodular thyroid disease[J]. N Engl J Med, 1998,338(20):1438-1447. DOI: 10.1056/NEJM199805143382007.
[53] Papini E, Petrucci L, Guglielmi R, et al. Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules[J]. J Clin Endocrinol Metab, 1998,83(3):780-783. DOI: 10.1210/jcem.83.3.4615.
[54] Grussendorf M, Reiners C, Paschke R, et al. Reduction of thyroid nodule volume by levothyroxine and iodine alone and in combination: a randomized, placebo-controlled trial[J]. J Clin Endocrinol Metab, 2011,96(9):2786-2795. DOI: 10.1210/jc.2011-0356.
[55] Nygaard B, Hegedüs L, Nielsen KG, et al. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules[J]. Clin Endocrinol(Oxf), 1999,50(2):197-202. DOI: 10.1046/j.1365-2265.1999.00635.x.
[56] Ross DS. Radioiodine therapy for hyperthyroidism[J]. N Engl J Med, 2011,364(6):542-550. DOI: 10.1056/NEJMct1007101.
[57] Ceccarelli C, Bencivelli W, Vitti P, et al. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study[J]. Clin Endocrinol(Oxf), 2005,62(3):331-335. DOI: 10.1111/j.1365-2265.2005.02218.x.
[58] Mariani G, Tonacchera M, Grosso M, et al. The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders, Part 1: Hyperthyroidism[J]. J Nucl Med, 2021,62(3):304-312. DOI: 10.2967/jnumed.120.243170.
[59] Yang CC, Hsu Y, Liou JY. Efficacy of Ethanol Ablation for Benign Thyroid Cysts and Predominantly Cystic Nodules: A Systematic Review and Meta-Analysis[J]. Endocrinol Metab(Seoul), 2021,36(1):81-95. DOI: 10.3803/EnM.2020.833.
[60] Cai W, Liu S, Yu X, et al. Is partial ablation appropriate for benign thyroid nodules? A retrospective study with long-term follow-up after microwave ablation[J]. Int J Hyperthermia, 2021,38(1):923-930. DOI: 10.1080/02656736.2021.1936217.
[61] Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology[J]. N Engl J Med, 2012,367(8):705-715. DOI: 10.1056/NEJMoa1203208.
[62] Rosario PW. Thyroid nodules with atypia or follicular lesions of undetermined significance(Bethesda Category III): importance of ultrasonography and cytological subcategory[J]. Thyroid, 2014,24(7):1115-1120. DOI: 10.1089/thy.2013.0650.
[63] Papaleontiou M, Haymart MR. Thyroid nodules and cancer during pregnancy, post-partum and preconception planning: Addressing the uncertainties and challenges[J]. Best Pract Res Clin Endocrinol Metab, 2020,34(4):101363. DOI: 10.1016/j.beem.2019.101363.
[64] Kung AW, Chau MT, Lao TT, et al. The effect of pregnancy on thyroid nodule formation[J]. J Clin Endocrinol Metab, 2002,87(3):1010-1014. DOI: 10.1210/jcem.87.3.8285.
[65] 《妊娠和产后甲状腺疾病诊治指南》(第2版)编撰委员会, 中华医学会内分泌学分会, 中华医学会围产医学分会. 妊娠和产后甲状腺疾病诊治指南(第2版)[J]. 中华内分泌代谢杂志, 2019,35(8):636-665. DOI: 10.3760/cma.j.issn.1000-6699.2019.08.003.
[66] Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum[J]. Thyroid, 2017,27(3):315-389. DOI: 10.1089/thy.2016.0457.
[67] Baloch ZW, Asa SL, Barletta JA, et al. Overview of the 2022 WHO Classification of Thyroid Neoplasms[J]. Endocr Pathol, 2022,33(1):27-63. DOI: 10.1007/s12022-022-09707-3.
[68] Miranda-Filho A, Lortet-Tieulent J, Bray F, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study[J]. Lancet Diabetes Endocrinol, 2021,9(4):225-234. DOI: 10.1016/S2213-8587(21)00027-9.
[69] Lim H, Devesa SS, Sosa JA, et al. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013[J]. JAMA, 2017,317(13):1338-1348. DOI: 10.1001/jama.2017.2719.
[70] Davies L, Morris LG, Haymart M, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: The Increasing Incidence of Thyroid Cancer [J]. Endocr Pract, 2015,21(6):686-696. DOI: 10.4158/EP14466.DSCR.
[71] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. DOI: 10.3322/caac.21338.
[72] Zheng RS, Zhang SW, Zeng HM, et al. Cancer incidence and mortality in China, 2016 [J]. J Natl Cancer Cent, 2022,2(1):1-9. DOI: 10.1016/j.jncc.2022.02.002.
[73] 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019,41(1):19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.008.
[74] Kitahara CM, Pfeiffer RM, Sosa JA, et al. Impact of Overweight and Obesity on US Papillary Thyroid Cancer Incidence Trends(1995-2015)[J]. J Natl Cancer Inst, 2020,112(8):810-817. DOI: 10.1093/jnci/djz202.
[75] 中国医师协会外科医师分会甲状腺外科医师委员会, 中国研究型医院学会甲状腺疾病专业委员会. 分化型甲状腺癌术后管理中国专家共识(2020版)[J]. 中国实用外科杂志, 2020,40(9):1021-1028. DOI: 10.19538/j.cjps.issn1005-2208.2020.09.04.
[76] 中华人民共和国国家卫生健康委员会. 甲状腺癌诊疗规范(2018年版)[J]. 中华普通外科学文献(电子版), 2019,13(1):1-15. DOI: 10.3877/cma.j.issn.1674-0793.2019.01.001.
[77] 中国超声医学工程学会浅表器官及外周血管专业委员会. 甲状腺及相关颈部淋巴结超声若干临床常见问题专家共识(2018版)[J]. 中国超声医学杂志, 2019,35(3):193-204. DOI: 10.3969/j.issn.1002-0101.2019.03.001.
[78] Lee Y, Kim JH, Baek JH, et al. Value of CT added to ultrasonography for the diagnosis of lymph node metastasis in patients with thyroid cancer[J]. Head Neck, 2018,40(10):2137-2148. DOI: 10.1002/hed.25202.
[79] Suh CH, Baek JH, Choi YJ, et al. Performance of CT in the Preoperative Diagnosis of Cervical Lymph Node Metastasis in Patients with Papillary Thyroid Cancer: A Systematic Review and Meta-Analysis[J]. AJNR Am J Neuroradiol, 2017,38(1):154-161. DOI: 10.3174/ajnr.A4967.
[80] Kaplan SL, Mandel SJ, Muller R, et al. The role of MR imaging in detecting nodal disease in thyroidectomy patients with rising thyroglobulin levels[J]. AJNR Am J Neuroradiol, 2009,30(3):608-612. DOI: 10.3174/ajnr.A1405.
[81] Kim DH, Kim SJ. Diagnostic role of F-18 FDG PET/CT for preoperative lymph node staging in thyroid cancer patients; A systematic review and metaanalysis[J]. Clin Imaging, 2020,65:100-107. DOI: 10.1016/j.clinimag.2020.04.030.
[82] Hauch A, Al-Qurayshi Z, Randolph G, et al. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons[J]. Ann Surg Oncol, 2014,21(12):3844-3852. DOI: 10.1245/s10434-014-3846-8.
[83] Lee J, Park JH, Lee CR, et al. Long-term outcomes of total thyroide-ctomy versus thyroid lobectomy for papillary thyroid microca-rcinoma: comparative analysis after propensity score matching[J]. Thyroid, 2013,23(11):1408-1415. DOI: 10.1089/thy.2012.0463.
[84] Zhang C, Li Y, Li J, et al. Total thyroidectomy versus lobectomy for papillary thyroid cancer: A systematic review and meta-analysis[J]. Medicine(Baltimore), 2020,99(6):e19073. DOI: 10.1097/MD.0000000000019073.
[85] Kim SK, Park I, Woo JW, et al. Total thyroidectomy versus lobectomy in conventional papillary thyroid microcarcinoma: Analysis of 8,676 patients at a single institution[J]. Surgery, 2017,161(2):485-492. DOI: 10.1016/j.surg.2016.07.037.
[86] Takami H, Ozaki O, Ito K. Familial nonmedullary thyroid cancer: an emerging entity that warrants aggressive treatment[J]. Arch Surg, 1996,131(6):676. DOI: 10.1001/archsurg.1996.01430180102023.
[87] Deaconson TF, Wilson SD, Cerletty JM, et al. Total or near total thyroidectomy versus limited resection for radiation-associated thyroid nodules: a twelve-year follow-up of patients in a thyroid screening program[J]. Surgery, 1986,100(6):1116-1120.
[88] Lim ST, Jeon YW, Suh YJ. Correlation Between Surgical Extent and Prognosis in Node-Negative, Early-Stage Papillary Thyroid Carcinoma Originating in the Isthmus[J]. World J Surg, 2016,40(2):344-349. DOI: 10.1007/s00268-015-3259-2.
[89] Vasileiadis I, Boutzios G, Karalaki M, et al. Papillary thyroid carcinoma of the isthmus: Total thyroidectomy or isthmusectomy?[J]. Am J Surg, 2018,216(1):135-139. DOI: 10.1016/j.amjsurg.2017.09.008.
[90] Nixon IJ, Ganly I, Patel SG, et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy[J]. Surgery, 2012,151(4):571-579. DOI: 10.1016/j.surg.2011.08.016.
[91] Kluijfhout WP, Pasternak JD, Lim J, et al. Frequency of High-Risk Characteristics Requiring Total Thyroidectomy for 1-4 cm Well-Differen-tiated Thyroid Cancer[J]. Thyroid, 2016,26(6):820-824. DOI: 10.1089/thy.2015.0495.
[92] Adam MA, Pura J, Gu L, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients[J]. Ann Surg, 2014,260(4):601-607. DOI: 10.1097/SLA.0000000000000925.
[93] Hwangbo Y, Kim JM, Park YJ, et al. Long-Term Recurrence of Small Papillary Thyroid Cancer and Its Risk Factors in a Korean Multicenter Study[J]. J Clin Endocrinol Metab, 2017,102(2):625-633. DOI: 10.1210/jc.2016-2287.
[94] Zhang HS, Lee EK, Jung YS, et al. Total thyroidectomy's association with survival in papillary thyroid cancers and the high proportion of total thyroidectomy in low-risk patients: Analysis of Korean nationwide data [J]. Surgery, 2019,165(3):629-636. DOI: 10.1016/j.surg.2018.08.030.
[95] Zheng X, Peng C, Gao M, et al. Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1,587 patients[J]. Cancer Biol Med, 2019,16(1):121-130. DOI: 10.20892/j.issn.2095-3941.2018.0125.
[96] Sun RH, Li C, Zhou YQ, et al. Predictive role of intraoperative clinicopathological features of the central compartment in estimating lymph nodes metastasis status[J]. Ann Transl Med, 2019,7(18):471. DOI: 10.21037/atm.2019.08.01.
[97] Xu SY, Yao JJ, Zhou W, et al. Clinical characteristics and ultrasono-graphic features for predicting central lymph node metastasis in clinically node-negative papillary thyroid carcinoma without capsule invasion[J]. Head Neck, 2019,41(11):3984-3991. DOI: 10.1002/hed.25941.
[98] Sun R, Sheng J, Zhou Y, et al. Relationship between the extent of central node dissection and parathyroid function preservation in thyroid cancer surgery[J]. Gland Surg, 2021,10(3):1093-1103. DOI: 10.21037/gs-21-121.
[99] Ondik MP, Dezfoli S, Lipinski L, et al. Secondary central compartment surgery for thyroid cancer[J]. Laryngoscope, 2009,119(10):1947-1950. DOI: 10.1002/lary.20589.
[100] Lefevre JH, Tresallet C, Leenhardt L, et al. Reoperative surgery for thyroid disease[J]. Langenbecks Arch Surg, 2007,392(6):685-691. DOI: 10.1007/s00423-007-0201-6.
[101] 汪菁, 王圣应. 中央区的界定及细化在甲状腺癌治疗中的意义[J]. 中华耳鼻咽喉头颈外科杂志, 2018,53(4):312-316. DOI: 10.3760/cma.j.issn.1673-0860.2018.04.016.
[102] 中国抗癌协会甲状腺癌专业委员会(CATO). 甲状腺微小乳头状癌诊断与治疗中国专家共识(2016版)[J]. 中国肿瘤临床, 2016,43(10):405-411. DOI: 10.3969/j.issn.1000-8179.2016.10.001.
[103] Ito Y, Onoda N, Okamoto T. The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: Core questions and recommendations for treatments of thyroid cancer[J]. Endocr J, 2020,67(7):669-717. DOI: 10.1507/endocrj.EJ20-0025.
[104] Berber E, Bernet V, Fahey TJ 3rd, et al. American Thyroid Association Statement on Remote-Access Thyroid Surgery[J]. Thyroid, 2016,26(3):331-337. DOI: 10.1089/thy.2015.0407.
[105] 中国医师协会外科医师分会甲状腺外科医师委员会, 中国研究型医院学会甲状腺疾病专业委员会. 机器人手术系统辅助甲状腺和甲状旁腺手术专家共识[J]. 中国实用外科杂志, 2016,36(11):1165-1170. DOI: 10.7504/CJPS.ISSN1005-2208.2016.11.08.
[106] 中国医师协会外科医师分会甲状腺外科医师委员会, 中国研究型医院学会甲状腺疾病专业委员会, 海峡两岸医药卫生交流协会海西甲状腺微创美容外科专家委员会, 等. 经胸前入路腔镜甲状腺手术专家共识(2017版)[J]. 中国实用外科杂志, 2017,37(12):1369-1373. DOI: 10.19538/j.cjps.issn1005-2208.2017.12.14.
[107] 王平, 吴国洋, 田文, 等. 经口腔前庭入路腔镜甲状腺手术专家共识(2018版)[J]. 中国实用外科杂志, 2018,38(10):1104-1107. DOI: 10.19538/j.cjps.issn1005-2208.2018.10.02.
[108] 王宇, 李崔伟, 史潇, 等. 腔镜辅助手术与开放手术治疗cN0期甲状腺乳头状癌的对比[J]. 中国肿瘤临床, 2019,46(20):1051-1055. DOI: 10.3969/j.issn.1000-8179.2019.20.760.
[109] 郑传铭, 徐加杰, 蒋烈浩, 等. 无充气腋窝入路完全腔镜下甲状腺叶切除的方法——葛-郑氏七步法[J]. 中国普通外科杂志, 2019,28(11):1336-1341. DOI: 10.7659/j.issn.1005-6947.2019.11.003.
[110] 王佳峰, 徐加杰, 蒋烈浩, 等. 无充气腋窝入路完全腔镜下甲状腺癌根治术对术后颈部功能影响的初步研究[J]. 中华内分泌外科杂志, 2021,15(1):10-14. DOI: 10.3760/cma.j.cn.115807-20200508-00151.
[111] 李秀萍, 俞红梅, 徐志伟, 等. 改良无充气经腋窝腔镜甲状腺手术治疗甲状腺微小乳头状癌的疗效分析[J]. 中华内分泌外科杂志, 2021,15(3):273-277. DOI: 10.3760/cma.j.cn.115807-20200701-00206.
[112] Zheng G, Xu J, Wu G, et al. Transoral versus gasless transaxillary endoscopic thyroidectomy: a comparative study[J]. Updates Surg, 2022,74(1):295-302. DOI: 10.1007/s13304-021-01062-y.
[113] Son SK, Kim JH, Bae JS, et al. Surgical safety and oncologic effectiveness in robotic versus conventional open thyroidectomy in thyroid cancer: a systematic review and meta-analysis[J]. Ann Surg Oncol, 2015,22(9):3022-3032. DOI: 10.1245/s10434-015-4375-9.
[114] Tae K, Ji YB, Song CM, et al. Robotic and Endoscopic Thyroid Surgery: Evolution and Advances[J]. Clin Exp Otorhinolaryngol, 2019,12(1):1-11. DOI: 10.21053/ceo.2018.00766.
[115] Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis[J]. Thyroid, 2016,26(10):1343-1421. DOI: 10.1089/thy.2016.0229.
[116] 章德广, 高力, 谢磊, 等. 改良Miccoli手术颈侧区淋巴结清扫术治疗甲状腺乳头状癌130例临床分析[J]. 中华外科杂志, 2016,54(11):864-869. DOI: 10.3760/cma.j.issn.0529-5815.2016.11.015.
[117] He Q, Zhu J, Zhuang D, et al. Robotic lateral cervical lymph node dissection via bilateral axillo-breast approach for papillary thyroid carcinoma: a single-center experience of 260 cases[J]. J Robot Surg, 2020,14(2):317-323. DOI: 10.1007/s11701-019-00986-3.
[118] Lee IA, Kim K, Kim JK, et al. Comparison of Surgical Outcomes between Robotic Transaxillary and Conventional Open Thyroidectomy in Pediatric Thyroid Cancer[J]. Cancers(Basel), 2021,13(13):3293. DOI: 10.3390/cancers13133293.
[119] Liu Z, Li Y, Wang Y, et al. Comparison of the transoral endoscopic thyroidectomy vestibular approach and open thyroidectomy: A propensity score-matched analysis of surgical outcomes and safety in the treatment of papillary thyroid carcinoma[J]. Surgery, 2021,170(6):1680-1686. DOI: 10.1016/j.surg.2021.06.032.
[120] Hermann M, Alk G, Roka R, et al. Laryngeal recurrent nerve injury in surgery for benign thyroid diseases: effect of nerve dissection and impact of individual surgeon in more than 27,000 nerves at risk[J]. Ann Surg, 2002,235(2):261-268. DOI: 10.1097/00000658-200202000-00015.
[121] Chandrasekhar SS, Randolph GW, Seidman MD, et al. Clinical practice guideline: improving voice outcomes after thyroid surgery[J]. Otolaryngol Head Neck Surg, 2013,148(6 Suppl):S1-S37. DOI: 10.1177/0194599813487301.
[122] 孙辉, 刘晓莉. 甲状腺及甲状旁腺手术中神经电生理监测临床指南(中国版)——解读与进展[J]. 中华内分泌外科杂志, 2014,8(1):1-3,11. DOI: 10.3760/cma.j.issn.1674-6090.2014.01.001.
[123] Chan WF, Lang BH, Lo CY. The role of intraoperative neuromonitoring of recurrent laryngeal nerve during thyroidectomy: a comparative study on 1000 nerves at risk[J]. Surgery, 2006,140(6):866-873. DOI: 10.1016/j.surg.2006.07.017.
[124] Giordano D, Valcavi R, Thompson GB, et al. Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature[J]. Thyroid, 2012,22(9):911-917. DOI: 10.1089/thy.2012.0011.
[125] Lorente-Poch L, Sancho JJ, Ruiz S, et al. Importance of in situ preservation of parathyroid glands during total thyroidectomy[J]. Br J Surg, 2015,102(4):359-367. DOI: 10.1002/bjs.9676.
[126] Li ZY, Tian W, Cai HK, et al. Clinical manifestations and manage-ments of post-neck dissection chylothorax[J]. Chin Med J(Engl), 2013,126(13):2570-2572.
[127] 樊友本, 郑起. 局部晚期甲状腺癌的多科联合诊治[M]. 上海:上海交通大学出版社, 2017.
[128] 刘志艳, 周庚寅, Kennichi Kakudo, 等. 2017版WHO甲状腺肿瘤分类解读[J]. 中华病理学杂志, 2018,47(4):302-306. DOI: 10.3760/cma.j.issn.0529-5807.2018.04.017.
[129] 刘志艳. 分化性甲状腺癌形态学谱系与分子生物学特征[J]. 中华病理学杂志, 2020,49(3):284-288. DOI: 10.3760/cma.j.issn.0529-5807.2020.03.018.
[130] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021[J]. 肿瘤预防与治疗, 2021,34(12):1164-1200. DOI: 10.3969/j.issn.1674-0904.2021.12.013.
[131] Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009,19(11):1167-1214. DOI: 10.1089/thy.2009.0110.
[132] Padovani RP, Kasamatsu TS, Nakabashi CC, et al. One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy[J]. Thyroid, 2012,22(9):926-930. DOI: 10.1089/thy.2012.0099.
[133] Giovanella L, Duntas LH. Management of endocrine disease: The role of rhTSH in the management of differentiated thyroid cancer: pros and cons[J]. Eur J Endocrinol, 2019,181(4):R133-R145. DOI: 10.1530/EJE-19-0149.
[134] Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioi-odine and thyrotropin alfa in thyroid cancer[J]. N Engl J Med, 2012,366(18):1674-1685. DOI: 10.1056/NEJMoa1109589.
[135] Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer[J]. N Engl J Med, 2012,366(18):1663-1673. DOI: 10.1056/NEJMoa1108586.
[136] Dehbi HM, Mallick U, Wadsley J, et al. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer(HiLo): long-term results of an open-label, non-inferiority randomised controlled trial[J]. Lancet Diabetes Endocrinol, 2019,7(1):44-51. DOI: 10.1016/S2213-8587(18)30306-1.
[137] Schlumberger M, Leboulleux S, Catargi B, et al. Outcome after ablation in patients with low-risk thyroid cancer(ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial[J]. Lancet Diabetes Endocrinol, 2018,6(8):618-626. DOI: 10.1016/S2213-8587(18)30113-X.
[138] Robenshtok E, Tuttle RM. Role of Recombinant Human Thyrotropin(rhTSH)in the Treatment of Well-Differentiated Thyroid Cancer[J]. Indian J Surg Oncol, 2012,3(3):182-189. DOI: 10.1007/s13193-011-0115-1.
[139] Donahue KP, Shah NP, Lee SL, et al. Initial staging of differentiated thyroid carcinoma: continued utility of posttherapy 131I whole-body scintigraphy[J]. Radiology, 2008,246(3):887-894. DOI: 10.1148/radiol.2463061328.
[140] Durante C, Attard M, Torlontano M, et al. Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas[J]. J Clin Endocrinol Metab, 2010,95(11):4882-4888. DOI: 10.1210/jc.2010-0762.
[141] Ma C, Feng F, Wang S, et al. Chinese Data of Efficacy of Low- and High-Dose Iodine-131 for the Ablation of Thyroid Remnant[J]. Thyroid, 2017,27(6):832-837. DOI: 10.1089/thy.2015.0658.
[142] Dong P, Wang L, Qu Y, et al. Low- and high-dose radioiodine ablation for low-/intermediate-risk differentiated thyroid cancer in China: Large randomized clinical trial[J]. Head Neck, 2021,43(4):1311-1320. DOI: 10.1002/hed.26594.
[143] James DL, Ryan ÉJ, Davey MG, et al. Radioiodine Remnant Ablation for Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis[J]. JAMA Otolaryngol Head Neck Surg, 2021,147(6):544-552. DOI: 10.1001/jamaoto.2021.0288.
[144] 中华医学会核医学分会. 131I治疗分化型甲状腺癌指南(2021版)[J]. 中华核医学与分子影像杂志, 2021,41(4):218-241. DOI: 10.3760/cma.j.cn321828-20201113-00412.
[145] Cheng L, Sa R, Luo Q, et al. Unexplained Hyperthyroglobulinemia in Differentiated Thyroid Cancer Patients as an Indication for Radioiodine Adjuvant Therapy: A Prospective Multicenter Study[J]. J Nucl Med, 2021,62(1):62-68. DOI: 10.2967/jnumed.120.243642.
[146] Chow SM, Yau S, Kwan CK, et al. Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition[J]. Endocr Relat Cancer, 2006,13(4):1159-1172. DOI: 10.1677/erc.1.01320.
[147] Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy[J]. J Clin Endocrinol Metab, 2006,91(8):2892-2899. DOI: 10.1210/jc.2005-2838.
[148] Van Nostrand D, Atkins F, Yeganeh F, et al. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma[J]. Thyroid, 2002,12(2):121-134. DOI: 10.1089/105072502753 522356.
[149] Lassmann M, Reiners C, Luster M. Dosimetry and thyroid cancer: the individual dosage of radioiodine[J]. Endocr Relat Cancer, 2010,17(3):R161-R172. DOI: 10.1677/ERC-10-0071.
[150] Verburg FA, Hänscheid H, Biko J, et al. Dosimetry-guided high-activity(131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience[J]. Eur J Nucl Med Mol Imaging, 2010,37(5):896-903. DOI: 10.1007/s00259-009-1303-x.

相似文献/References:

[1]杨成会,缪珩.二甲双胍在甲状腺疾病治疗中的作用[J].国际内分泌代谢杂志,2015,(04):255.[doi:10.3760/cma.j.issn.1673-4157.2015.04.011]
　Yang Chenghui,Miao Heng..Roles of metformin in the treatment of thyroid diseases[J].International Journal of Endocrinology and Metabolism,2015,(02):255.[doi:10.3760/cma.j.issn.1673-4157.2015.04.011]
[2]梁绮君 余寿益 李淑华 胡晨鸣 杨焱.甲状腺结节与代谢综合征的相关性研究[J].国际内分泌代谢杂志,2015,(05):293.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.002]
　Liang Qijun,Yu Shouyi,Li Shuhua,et al.Association of thyroid nodule and metabolic syndrome[J].International Journal of Endocrinology and Metabolism,2015,(02):293.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.002]
[3]耿艳,徐书杭,鲁一兵,等.非编码RNA在分化型甲状腺癌分子诊断中的作用[J].国际内分泌代谢杂志,2017,37(02):101.[doi:10.3760/cma.j.issn.1673-4157.2017.02.008]
　Geng Yan*,Xu Shuhang,Lu Yibing,et al.Noncoding RNA in molecular diagnosis of differentiated thyroid cancer[J].International Journal of Endocrinology and Metabolism,2017,37(02):101.[doi:10.3760/cma.j.issn.1673-4157.2017.02.008]
[4]郑仁东 张会峰 胡咏新 曹雯 曹琳 孙洪平 褚晓秋 刘克冕 刘超.男性2型糖尿病患者甲状腺结节 与内分泌激素的相关性研究[J].国际内分泌代谢杂志,2018,38(04):222.[doi:10.3760/cma.j.issn.1673-4157.2018.04.002]
　Zheng Rendong,Zhang Huifeng,Hu Yongxin,et al.Association of thyroid nodules with endocrine hormones in male patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2018,38(02):222.[doi:10.3760/cma.j.issn.1673-4157.2018.04.002]
[5]陈茉 徐书杭 刘超.良性甲状腺结节的热消融治疗进展[J].国际内分泌代谢杂志,2019,39(04):248.[doi:10.3760/cma.j.issn.1673-4157.2019.04.008]
　Chen Mo,Xu Shuhang,Liu Chao.Advancement of thermal ablation on benign thyroid nodules[J].International Journal of Endocrinology and Metabolism,2019,39(02):248.[doi:10.3760/cma.j.issn.1673-4157.2019.04.008]
[6]周一帆 季沁 陈国芳 褚晓秋 陈茉 丁文波 胡欣 相萍萍 曾铮 王建华 徐书杭 刘超.TI-RADS对细胞学结果不确定甲状腺结节的诊断价值[J].国际内分泌代谢杂志,2019,39(04):226.[doi:10.3760/cma.j.issn.1673-4157.2019.04.003]
　Zhou Yifan,Ji Qin,Chen Guofang,et al.Clinical value of TI-RADS in the diagnosis of thyroid nodules with indeterminate cytology[J].International Journal of Endocrinology and Metabolism,2019,39(02):226.[doi:10.3760/cma.j.issn.1673-4157.2019.04.003]
[7]周一帆 王建华 徐书杭.甲状腺细胞病理学Bethesda报告系统的更新及研究进展[J].国际内分泌代谢杂志,2020,40(03):175.[doi:10.3760/cma.j.issn.1673-4157.2020.03.007]
　Zhou Yifan,Wang Jianhua,Xu Shuhang.Update and research progress of the Bethesda system for reporting thyroid cytopathology[J].International Journal of Endocrinology and Metabolism,2020,40(02):175.[doi:10.3760/cma.j.issn.1673-4157.2020.03.007]
[8]杨晶晶,徐书杭,刘超.针穿活检用于甲状腺结节诊断的研究进展[J].国际内分泌代谢杂志,2021,41(01):20.[doi:10.3760/cma.j.cn121383-20200511-05018]
　Yang Jingjing,Xu Shuhang,et al.Update on core needle biopsy in the diagnosis of thyroid nodules[J].International Journal of Endocrinology and Metabolism,2021,41(02):20.[doi:10.3760/cma.j.cn121383-20200511-05018]
[9]李静,李曙光,乐岭.二甲双胍抑制分化型甲状腺癌的作用及机制[J].国际内分泌代谢杂志,2021,41(01):28.[doi:10.3760/cma.j.cn121383-20200514-05032]
　Li Jing,Li Shuguang,Yue Ling..Effects and mechanisms of metformin on differentiated thyroid cancer[J].International Journal of Endocrinology and Metabolism,2021,41(02):28.[doi:10.3760/cma.j.cn121383-20200514-05032]
[10]田勍,洪天配.甲状腺结节诊治过程中的难点与应对[J].国际内分泌代谢杂志,2021,41(06):557.[doi:10.3760/cma.j.cn121383-20210727-07074]
　Tian Qing,Hong Tianpei..Difficulties and countermeasures in the diagnosis and treatment of thyroid nodules[J].International Journal of Endocrinology and Metabolism,2021,41(02):557.[doi:10.3760/cma.j.cn121383-20210727-07074]

更新日期/Last Update: 2023-04-15